Conference Coverage

Lithium lowers osteoporosis risk in bipolar patients…and orthopedists take notice


 

AT APA 2022

Findings important for orthopedists

The unique properties observed with lithium have caught the attention of some in orthopedics, and researchers with the University of Toronto – having found intriguing bone healing with lithium in preclinical rodent studies – are currently conducting a first-of-its-kind multicenter, randomized, controlled clinical trial evaluating the potential effects of lithium in the healing of bone fractures.

Division of Orthopedic Surgery, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada courtesy Sunnybrook Health Sciences Centre

Dr. Diane Nam

Diane Nam, MD, of the division of orthopedic surgery, Sunnybrook Health Sciences Centre, Toronto, and lead investigator on the study, said in an interview that “I’m not surprised by [Dr. Ostergaard’s] paper because it’s consistent with what we have observed about the positive effects on bone healing.”

Dr. Nam and associates have already established administration parameters for their clinical study, determining that optimal effects in fracture healing appear to require that lithium treatment not begin at the time of fracture, but 2 weeks afterward, when new bone is ready to be laid down at the fracture site. In their trial, low daily doses of lithium (at 300 mg) are given only for a duration of 2 weeks.

“While our current trial is intended for a healthy, nonosteoporotic adult population, we have also demonstrated in our preclinical studies that lithium is just as effective in improving fracture healing in an osteoporotic model when the timing of administration is slightly delayed,” she said. “How this is relevant and translatable in patients with bipolar disorder requires further study.”

Dr. Nam said her research team thinks that “not only will the fracture heal faster, but it will heal reliably as delayed or impaired fracture healing remains a significant orthopedic problem.”

While details are not yet available, a preliminary analysis has shown results “going in a positive direction,” enough for the team to be granted funding for the multicenter trial.

Dr. Ostergaard and Dr. Nam reported no disclosures or conflicts.

Pages

Recommended Reading

FDA okays first sublingual med for agitation in serious mental illness
MDedge Psychiatry
New combination med for severe mental illness tied to less weight gain
MDedge Psychiatry
High antipsychotic switch rates suggest ‘suboptimal’ prescribing for first-episode psychosis
MDedge Psychiatry
The woman who kept passing out
MDedge Psychiatry
Managing bipolar disorder in women who are pregnant
MDedge Psychiatry
Higher ‘chemical restraint’ rates in Black psych patients in the ED
MDedge Psychiatry
Mood instability in childhood as a precursor to bipolar disorder
MDedge Psychiatry
Do psychotropic meds raise or lower COVID risk in psych patients?
MDedge Psychiatry
Neuropsychiatric risks of COVID-19: New data
MDedge Psychiatry
Multiple mental health woes? Blame it on genetics
MDedge Psychiatry